Dr. Naveen Pemmaraju, MD
Claim this profileMD Anderson Cancer Center
Area of expertise
BPDCN
Naveen Pemmaraju, MD has run 5 trials for BPDCN. Some of their research focus areas include:
Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju, MD has run 5 trials for Blastic Plasmacytoid Dendritic Cell Neoplasm. Some of their research focus areas include:
Affiliated Hospitals
M D Anderson Cancer Center
M D Anderson
Clinical Trials Naveen Pemmaraju, MD is currently running
Venetoclax + Tagraxofusp-erzs + Chemotherapy
for BPDCN
This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant protein consisting of IL-3 linked to a toxic agent called DT. IL-3 attaches to IL-3 receptors on tumor cells in a targeted way and delivers DT to kill them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and SL-401 with chemotherapy may be an effective treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Recruiting
1 award
Phase 2
12 criteria
SL-401 + Azacitidine/Venetoclax
for AML and MDS
This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS. The interventions involved in this study are: * SL-401 * Azacitidine * Venetoclax
Recruiting
1 award
Phase 1
More about Naveen Pemmaraju, MD
Clinical Trial Related
5 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Naveen Pemmaraju, MD has experience with
- Venetoclax
- Cyclophosphamide
- Cytarabine
- Azacitidine
- Fludarabine
- Dexamethasone
Breakdown of trials Naveen Pemmaraju, MD has run
BPDCN
Blastic Plasmacytoid Dendritic Cell Neoplasm
Acute Myeloid Leukemia
Myelofibrosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Naveen Pemmaraju, MD specialize in?
Naveen Pemmaraju, MD focuses on BPDCN and Blastic Plasmacytoid Dendritic Cell Neoplasm. In particular, much of their work with BPDCN has involved CD123 positive patients, or patients who are Stage I.
Is Naveen Pemmaraju, MD currently recruiting for clinical trials?
Yes, Naveen Pemmaraju, MD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Naveen Pemmaraju, MD has studied deeply?
Yes, Naveen Pemmaraju, MD has studied treatments such as Venetoclax, Cyclophosphamide, Cytarabine.
What is the best way to schedule an appointment with Naveen Pemmaraju, MD?
Apply for one of the trials that Naveen Pemmaraju, MD is conducting.
What is the office address of Naveen Pemmaraju, MD?
The office of Naveen Pemmaraju, MD is located at: MD Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the MD Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.